Director Dealing

RNS Number : 8452K

Proteome Sciences PLC

05 January 2016

 

 

 

PRESS RELEASE

                                                                                                                                     5 January 2016

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director Dealing

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that it has a total direct and indirect interest in 36,573,125 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") equivalent to 16.04% of Proteome Sciences' total issued share capital. The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 36,573,125 Ordinary Shares of the Company representing 16.04% of the issued share capital of the Company.

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer
Ian Pike, Chief Operating Officer	Tel: [phone]
Geoff Ellis, Finance Director
finnCap Limited (Nominated adviser & broker)
Geoff Nash/James Thompson	Tel: [phone]
Public Relations
IKON Associates
Adrian Shaw	Email: [e-mail]
Tel: [phone] Mob: [phone]	Tel:   [phone] Mob: [phone]

Notes to Editors:

About Proteome Sciences plc (www.proteomics.com)

With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways and in protein biomarker discovery, validation and assay development.

Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.

 PS Biomarker Services^® provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.

 

END

 

 

RDSSSESUIFMSELF